Latest News
Investor Relations
Latest News
January 13, 2025 07:00 am
BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million
January 8, 2025 07:00 am
BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®
January 2, 2025 07:00 am
BioStem Technologies CEO to Present at Biotech Showcase 2025
November 25, 2024 07:00 am
BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts
November 20, 2024 07:00 am
BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global
November 12, 2024 07:29 am
BioStem Technologies Reports Record Third Quarter 2024 Revenue of $82.6 Million
October 29, 2024 07:00 am
BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions
October 28, 2024 01:58 pm
BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
October 23, 2024 07:00 am